Total Payments
$3,257
2023 Payments
$15.03
Companies
32
Transactions
210
Medicare Patients
5,863
Medicare Billing
$471,946
Payment Breakdown by Category
Food & Beverage$3,040 (93.3%)
Education$216.91 (6.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,040 | 206 | 93.3% |
| Education | $216.91 | 4 | 6.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $907.49 | 69 | $0 (2021) |
| Janssen Biotech, Inc. | $276.31 | 19 | $0 (2022) |
| AbbVie Inc. | $257.84 | 18 | $0 (2021) |
| Boston Scientific Corporation | $239.67 | 15 | $0 (2022) |
| PFIZER INC. | $231.99 | 19 | $0 (2022) |
| Allergan, Inc. | $194.72 | 12 | $0 (2022) |
| NeoTract Inc. | $121.49 | 5 | $0 (2020) |
| TOLMAR Pharmaceuticals, Inc. | $106.26 | 6 | $0 (2020) |
| Janssen Products, LP | $99.95 | 1 | $0 (2017) |
| Dendreon Pharmaceuticals LLC | $80.32 | 4 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $15.03 | 1 | Coloplast Corp ($15.03) |
| 2022 | $241.35 | 14 | UROVANT SCIENCES INC ($50.10) |
| 2021 | $501.00 | 34 | Astellas Pharma US Inc ($159.64) |
| 2020 | $442.91 | 28 | Astellas Pharma US Inc ($121.08) |
| 2019 | $568.62 | 46 | Astellas Pharma US Inc ($134.10) |
| 2018 | $765.69 | 49 | Astellas Pharma US Inc ($121.09) |
| 2017 | $722.52 | 38 | Astellas Pharma US Inc ($371.58) |
All Payment Transactions
210 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/03/2023 | Coloplast Corp | SpeediCath (Device) | Food and Beverage | In-kind items and services | $15.03 | General |
| Category: Continence Care | ||||||
| 07/20/2022 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $19.47 | General |
| Category: Oncology | ||||||
| 06/15/2022 | Boston Scientific Corporation | rezum Generator (Device) | Food and Beverage | In-kind items and services | $19.23 | General |
| Category: rezum_URO | ||||||
| 05/19/2022 | PFIZER INC. | XTANDI (Drug), ORGOVYX | Food and Beverage | In-kind items and services | $16.17 | General |
| Category: ONCOLOGY | ||||||
| 05/18/2022 | UROVANT SCIENCES INC | GEMTESA (Drug) | Food and Beverage | Cash or cash equivalent | $17.29 | General |
| Category: Urology | ||||||
| 04/28/2022 | Endo Pharmaceuticals Inc. | XIAFLEX (Biological) | Food and Beverage | In-kind items and services | $16.75 | General |
| Category: UROLOGY | ||||||
| 04/20/2022 | Travere Therapeutics, Inc. | Thiola (Drug) | Food and Beverage | In-kind items and services | $24.04 | General |
| Category: Kidney Stones | ||||||
| 04/14/2022 | UROVANT SCIENCES INC | GEMTESA (Drug) | Food and Beverage | Cash or cash equivalent | $18.75 | General |
| Category: Urology | ||||||
| 04/07/2022 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $16.05 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 03/23/2022 | Allergan, Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $14.05 | General |
| Category: HYPERHYDROSIS | ||||||
| 03/02/2022 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $17.50 | General |
| Category: Oncology | ||||||
| 02/02/2022 | Antares Pharma, Inc. | NOCDURNA (Drug), XYOSTED | Food and Beverage | In-kind items and services | $16.97 | General |
| Category: NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS | ||||||
| 01/27/2022 | UROVANT SCIENCES INC | GEMTESA (Drug) | Food and Beverage | Cash or cash equivalent | $14.06 | General |
| Category: Urology | ||||||
| 01/20/2022 | Allergan, Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $14.08 | General |
| Category: HYPERHYDROSIS | ||||||
| 01/06/2022 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $16.94 | General |
| Category: Oncology | ||||||
| 12/15/2021 | UROVANT SCIENCES INC | GEMTESA (Drug) | Food and Beverage | Cash or cash equivalent | $15.45 | General |
| Category: Urology | ||||||
| 12/02/2021 | Antares Pharma, Inc. | XYOSTED (Drug) | Food and Beverage | In-kind items and services | $11.24 | General |
| Category: Testosterone Replacement Therapy | ||||||
| 11/19/2021 | AbbVie Inc. | LUPRON DEPOT (Drug) | Food and Beverage | In-kind items and services | $13.53 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/12/2021 | BOSTON SCIENTIFIC CORPORATION | ADVANTAGE (Device) | Food and Beverage | In-kind items and services | $21.81 | General |
| Category: PAIN MANAGEMENT | ||||||
| 10/27/2021 | Astellas Pharma US Inc | MYRBETRIQ (Drug) | Food and Beverage | In-kind items and services | $10.41 | General |
| Category: UROLOGY | ||||||
| 10/21/2021 | Myriad Genetic Laboratories, Inc. | Prolaris (Device) | Food and Beverage | Cash or cash equivalent | $12.02 | General |
| Category: Gene Expression Analysis Oncology | ||||||
| 10/20/2021 | Olympus America Inc. | iTIND System (Device) | Food and Beverage | In-kind items and services | $12.32 | General |
| Category: Urology Gynecology | ||||||
| 10/19/2021 | Allergan, Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $13.90 | General |
| Category: HYPERHYDROSIS | ||||||
| 10/15/2021 | Janssen Biotech, Inc. | ERLEADA (Drug), BALVERSA | Food and Beverage | In-kind items and services | $33.89 | General |
| Category: Oncology | ||||||
| 09/30/2021 | Astellas Pharma US Inc | MYRBETRIQ (Drug) | Food and Beverage | In-kind items and services | $9.11 | General |
| Category: UROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 12 | 1,128 | 5,012 | $362,148 | $82,636 |
| 2021 | 23 | 2,371 | 14,777 | $859,220 | $212,354 |
| 2020 | 26 | 2,364 | 3,082 | $726,566 | $176,956 |
Total Patients
5,863
Total Services
22,871
Medicare Billing
$471,946
Procedure Codes
73
All Medicare Procedures & Services
73 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2022 | 24 | 144 | $139,680 | $19,712 | 14.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 164 | 200 | $28,000 | $15,073 | 53.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 226 | 262 | $35,632 | $13,481 | 37.8% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Facility | 2022 | 114 | 134 | $66,195 | $7,433 | 11.2% |
| 52601 | Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | Facility | 2022 | 13 | 13 | $23,400 | $7,028 | 30.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 108 | 133 | $18,088 | $4,953 | 27.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 65 | 78 | $10,920 | $4,657 | 42.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 43 | 43 | $10,216 | $3,289 | 32.2% |
| 55700 | Biopsy of prostate gland | Facility | 2022 | 24 | 24 | $9,430 | $2,239 | 23.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 19 | 19 | $3,800 | $1,432 | 37.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 19 | 19 | $4,560 | $1,374 | 30.1% |
| 76872 | Ultrasound scan of pelvic region through rectum | Facility | 2022 | 24 | 25 | $2,292 | $606.86 | 26.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 14 | 14 | $2,800 | $503.25 | 18.0% |
| 81001 | Manual urinalysis test with examination using microscope, automated | Office | 2022 | 124 | 149 | $2,980 | $464.79 | 15.6% |
| 81003 | Automated urinalysis test | Office | 2022 | 136 | 151 | $1,812 | $338.64 | 18.7% |
| J1071 | Injection, testosterone cypionate, 1 mg | Office | 2022 | 11 | 3,604 | $2,343 | $49.21 | 2.1% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2021 | 35 | 278 | $269,660 | $40,249 | 14.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 447 | 611 | $83,096 | $35,798 | 43.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 247 | 335 | $46,900 | $30,146 | 64.3% |
| 52601 | Electro-removal of prostate through bladder canal (urethra) with control of bleeding using an endoscope | Facility | 2021 | 38 | 38 | $68,400 | $20,716 | 30.3% |
| 52000 | Diagnostic examination of the bladder and bladder canal (urethra) using an endoscope | Facility | 2021 | 216 | 281 | $132,221 | $16,521 | 12.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 181 | 251 | $34,136 | $11,465 | 33.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 89 | 89 | $21,360 | $9,784 | 45.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 78 | 111 | $15,540 | $7,432 | 47.8% |
| 52356 | Crushing of stone in urinary duct (ureter) with stent using an endoscope | Facility | 2021 | 18 | 22 | $41,800 | $6,645 | 15.9% |
About Dr. John Devine, MD
Dr. John Devine, MD is a Urology healthcare provider based in Manhattan, Kansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/24/2005. The National Provider Identifier (NPI) number assigned to this provider is 1376533075.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Devine, MD has received a total of $3,257 in payments from pharmaceutical and medical device companies, with $15.03 received in 2023. These payments were reported across 210 transactions from 32 companies. The most common payment nature is "Food and Beverage" ($3,040).
As a Medicare-enrolled provider, Devine has provided services to 5,863 Medicare beneficiaries, totaling 22,871 services with total Medicare billing of $471,946. Data is available for 3 years (2020–2022), covering 73 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Location Manhattan, KS
- Active Since 10/24/2005
- Last Updated 02/01/2011
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1376533075
Products in Payments
- XTANDI (Drug) $523.00
- Myrbetriq (Drug) $271.63
- Erleada (Drug) $155.72
- ZYTIGA (Drug) $136.94
- MYRBETRIQ (Drug) $122.78
- UroLift (Device) $121.49
- ERLEADA (Drug) $121.45
- LUPRON DEPOT (Drug) $115.68
- ELIGARD (Drug) $106.26
- REZUM (Device) $89.39
- VESICARE (Drug) $83.13
- PROVENGE (Drug) $80.32
- SpaceOAR (Device) $67.30
- BOTOX (Biological) $66.84
- GREENLIGHT (Device) $66.73
- GEMTESA (Drug) $65.55
- XIAFLEX (Biological) $60.27
- (815) Thiola (Drug) $59.36
- BOTOX THERAPEUTIC (Biological) $58.33
- Axumin (Drug) $57.36
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.